T 0056/24 (Oral azacytidine III/CELGENE) of 22.07.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T005624.20250722
- Date of decision
- 22 July 2025
- Case number
- T 0056/24
- Petition for review of
- -
- Application number
- 19213148.0
- IPC class
- A61P 15/08A61P 43/00A61K 31/7068A61P 1/18A61K 47/26A61P 35/00A61P 1/00A61K 9/20A61P 35/02A61K 9/28
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
- Applicant name
- Celgene Corporation
- Opponent name
- Lotus Pharmaceutical Co., Ltd.
SANDOZ AG
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Hoffmann Eitle Patent- und Rechtsanwälte
Partnerschaftsgesellschaft mbB
STADA Arzneimittel AG
Generics [UK] Limited - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention Art 83Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Keywords
- Novelty - (yes)
Novelty - implicit disclosure (no)
Remittal - (no)
Divisional application - added subject-matter (no)
Sufficiency of disclosure - (yes)
Inventive step - non-obvious modification
Late-filed evidence - admitted (no) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is maintained as granted.